Trial Profile
A Randomized, Phase III, Multicenter, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of ONARTUZUMAB (MetMAb) in Combination with Tarceva (Erlotinib) in Patients with Met Diagnostic-Positive Non-Small Cell Lung Cancer (NSCLC) Who Have Received Standard Chemotherapy for Advanced or Metastatic Disease
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 24 Jun 2022
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary) ; Onartuzumab (Primary)
- Indications Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Acronyms MetLUNG
- Sponsors Genentech
- 13 Jun 2019 Trial has been completed in UK.
- 22 Dec 2016 Results published in the Lancet Oncology
- 09 Sep 2015 Planned End Date changed from 1 Jun 2015 to 1 Dec 2015, according to ClinicalTrials.gov record